Investor Relations

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made by Executive Management.

Notice is hereby given of the annual general meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on

Wednesday, 3 December 2025 at 3:00 pm (CET)

at the company’s address at Baltorpbakken 13, 2750 Ballerup.

BOARD OF DIRECTORS

The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair.

The Board of Directors proposes that David Hale, Simon Hesse Hoffmann, Susanne Larsson, and Michael del Prado are all re-elected.

The notice for this year’s annual general meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish- and English-language versions. In the event of discrepancies, the English version shall prevail.

Ambu A/S offers the possibility of viewing the annual general meeting 2025 via live webcast on Ambu’s website.

Please refer to the notice for further information.

Download the full company announcement here in English.

Download the full company announcement here in Danish.

Today, Ambu releases its annual report for the 2024/25 financial year. For the full year, Ambu reported 13.1% organic revenue growth. This was driven by Endoscopy Solutions growing 15.4% and Anesthesia & Patient Monitoring growing 9.9%. Ambu’s EBIT margin before special items reached 13.0%, and the company’s free cash flow before acquisitions totaled DKK 407m. 

The financial outlook for the 2025/26 financial year is set as follows: 10-13% organic revenue growth and 12-14% reported EBIT margin before special items. Excluding tariff impacts of ~2%-pts, EBIT margin is expected to be 14-16% given the current schedule of expected tariffs. Mitigation action, including investing in Americas, are ongoing, and the effect will diminish over the coming years. 

“We have delivered another strong year at Ambu of double-digit organic growth and profitability, successfully concluding our turnaround with our ZOOM IN strategy and setting the stage for what’s next. We now are entering a new era of accelerated growth and greater impact in healthcare, driven by our ambition to achieve global endoscopy leadership. Our aim is clear: we want to help clinicians treat more patients – faster and better – through our innovative solutions that enhance efficiency, strengthen clinical performance, and improve patient outcomes in a pressured global healthcare industry. 

I am deeply energized by the opportunities ahead and grateful to my passionate colleagues worldwide, whose dedication and ingenuity have brought us this far. Together, we are ready to shape the future of endoscopy and redefine what’s possible.” 

Britt Meelby Jensen 
Chief Executive Officer 

Financial highlights for 2024/25 
Revenue for the full year was DKK 6,037m (DKK 5,391m), bringing the organic growth to 13.1% (13.8%) and the reported growth to 12.0% (12.9%). 

Endoscopy Solutions increased organically by 15.4% (19.7%). The Respiratory business group posted 15.4% (11.7%) organic growth, while the Urology, ENT, & GI business group posted 19.6% (29.6%) organic growth. 

Anesthesia & Patient Monitoring increased organically by 9.9% (6.1%).  

EBIT before special items (b.s.i.) for the full year was DKK 784m (DKK 645m), with an EBIT margin b.s.i. of 13.0% (12.0%). 

Free cash flow (FCF) before acquisitions totaled DKK 407m (DKK 524m) for the full year.  

Total distribution of cash of DKK 260m, consisting of a dividend of DKK 110m planned for proposal by the Board of Directors at the annual general meeting, as well as a DKK 150m share buy-back program. 

2025/26 financial guidance 

Organic revenue growth: 10-13%  

EBIT margin b.s.i.: 12-14%¹

¹⁾  14-16% excluding assumed tariff impact of ~2%-pts, given the current schedule of expected tariffs. Mitigation actions, including investing in Americas, are ongoing, and the effect will diminish over the coming years.  

DOWNLOAD AMBU’S REPORTS 
In addition to the Annual Report, which includes the company’s sustainability statement, Ambu also publishes its interim report for Q4 2024/25, Remuneration Report, and Corporate Governance Report for the 2024/25 financial year today. All full-year reports are attached and can also be accessed on Ambu.com/reports. 

Q4 earnings release 
Interim report for Q4 2024/25 (unaudited)

Statutory reports 
Annual Report 2024/25

Annual Report 2024/25 (ESEF tagged) 

Remuneration Report 2024/25

Corporate Governance Report 2024/25

Q4 2024/25 CONFERENCE CALL 
A conference call is broadcast live today, 5 November 2025 at 11:00 (CET), via Ambu.com/webcastQ42025. To ask questions during the Q&A session, please register prior to the call via Ambu.com/conferencecallQ42025register. Upon registration, you will receive an e-mail with information to access the call. 

The presentation can be downloaded at Ambu.com/presentations. 

Company announcement no. 2 2025/26